Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Sank Today

By Keith Speights – Jun 3, 2020 at 3:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Comments from Dr. Anthony Fauci and a decision by the White House weighed on the stock.

What happened

Shares of Inovio Pharmaceuticals (INO 2.68%) were sinking 12.8% lower as of 3:27 p.m. EDT on Wednesday. The decline appeared to be caused primarily by two factors.

Inovio's shares slipped earlier in the day following comments that Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), made in an interview with JAMA editor Howard Bauchner. Fauci stated that he was concerned that COVID-19 vaccines likely won't provide a long period of immunity.

The stock fell harder later in the day, though, after The New York Times reported that the Trump administration selected five COVID-19 vaccines as the most likely to be successful. Inovio didn't make the cut.

So what

Fauci's remarks caused the stocks of several companies that are developing COVID-19 vaccines to tumble early on Wednesday. He stated that the durability of immunity with types of coronaviruses other than SARS-CoV-2 (the coronavirus that causes COVID-19) ranges from three to six months and is "almost always less than a year."

Gloved hand holding COVID-19 vaccine syringe

Image source: Getty Images.

The bigger story, though, was that Inovio wasn't in the group of five COVID-19 vaccine candidates that are reportedly on the Trump administration's list. The vaccine candidates that did make the top five, according to the New York Times report, were ones being developed by AstraZeneca (AZN -0.13%) and the University of Oxford, Johnson & Johnson (JNJ -0.71%), Merck (MRK -0.60%), Moderna (MRNA 0.15%), and Pfizer (PFE -0.91%) and BioNTech (BNTX 0.96%).

Inovio is currently evaluating COVID-19 vaccine candidate INO-4800 in a phase 1 clinical study. The company's preclinical data for INO-4800 demonstrated the production of what Inovio referred to as "robust neutralizing antibodies and T cell response" against SARS-CoV-2. 

Now what

Inovio expects to report results from its phase 1 study of INO-4800 in June. The company hopes to begin a phase 2/3 clinical study in July or August pending FDA approval. In the meantime, it's likely that the biotech stock will remain highly volatile with big swings on positive and negative news related to the development of COVID-19 vaccines.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.73 (2.68%) $0.04
Pfizer Inc. Stock Quote
Pfizer Inc.
$43.76 (-0.91%) $0.40
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$86.12 (-0.60%) $0.52
Johnson & Johnson Stock Quote
Johnson & Johnson
$163.36 (-0.71%) $-1.17
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.84 (-0.13%) $0.07
Moderna, Inc. Stock Quote
Moderna, Inc.
$118.25 (0.15%) $0.18
BioNTech SE Stock Quote
BioNTech SE
$134.88 (0.96%) $1.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.